Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8629185 | ALLERGAN INC | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10398707 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(1 year, 2 months from now) | |
US8673341 | ALLERGAN INC | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(2 years from now) | |
US9149428 | ALLERGAN INC | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(3 years from now) | |
US10441543 | ALLERGAN INC | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(3 years from now) | |
US8206737 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(4 years from now) | |
US7799336 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(6 years from now) | |
US9492316 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
US9980974 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 4, 2023 |
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8038988 | ALLERGAN | Method of enhancing hair growth |
Aug, 2023
(6 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8986715 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(23 days ago) | |
US9226931 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(23 days ago) | |
US8632760 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(23 days ago) | |
US8263054 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(23 days ago) | |
US8758733 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(23 days ago) | |
US9216183 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(23 days ago) | |
US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(1 year, 3 months from now) |
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness
Dosage: SOLUTION/DROPS;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8278353 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8772338 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8309605 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8586630 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8524777 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US9155716 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8338479 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8299118 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US9241918 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8933120 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
US8933127 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) |
Market Authorisation Date: 31 August, 2010
Treatment: A method of lowering intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; Method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic